Axitinib is a VEGFR tyrosine kinase inhibitor mainly used for second-line treatment of advanced renal cell carcinoma. Its target population needs to be comprehensively evaluated based on disease progression, previous treatment, and special physiological status.

1. Basic indication population

(1) Advanced renal cell carcinoma: suitable for adult patients who have previously failed a systemic treatment, as a second-line treatment option.

(2) Advanced stage patients: metastatic clear cell carcinoma that has progressed after treatment with sunitinib or cytokines (such as IL-2).

2 populations with special physiological states

(1) Liver dysfunction: Mild to moderate damage (Child Pugh A/B grade) should be reduced to 50% of the initial dose, and severe damage (Child Pugh C grade) should be avoided.

(2) Renal insufficiency: Mild to moderate damage does not require dose adjustment, and there is a lack of safety data for patients with end-stage kidney disease or dialysis.

3 Forbidden Groups

(1) Pregnancy: Animal studies have shown embryotoxicity, and contraceptive measures should be taken during treatment and within one week after discontinuation.

(2) Breastfeeding period: Medication may be secreted into breast milk. Breastfeeding is prohibited during the treatment period and within 2 weeks after the last administration.

4. Caution should be exercised when using the target audience

(1) Cardiovascular disease: Hypertensive patients need to control to<150/90mmHg before medication can be administered, and continuous monitoring is required during treatment.

(2) Bleeding risk: Individuals with recent active bleeding or a history of major surgery need to assess their benefit risk ratio.